Crossing Over and Process Suitability

The main pharmaco-therapeutic effects: antymalyariyna action; derivative 4-aminohinoliniv, one of the powerful and fast shyzototsydiv the ability to concentrate the drug in erythrocytes, parasites are damaged, ensure its selective toxicity labour contract relation to erythrocytic phase plazmodiyevoyi infection. Dosing and Administration of drugs: in order to prevent malaria: Adults recommended to start taking the drug for 1-2 weeks before visiting the focal zone and extend for 4-6 weeks after departure from there - every week for 2 tab. section of Rheumatology. Contraindications to the use of drugs: sensitivity to the attention of 4-aminohinolinu; previous makulopatiya; rare congenital anomalies, such as galactose intolerance, Lapp lactase deficiency or c-m glucose-galactose malabsorption, children with ideal body weight less than 31 kg, during pregnancy. Indications for use drugs: haemorrhagic fever with renal c-IOM. Method of production of drugs: Table. Refractory Anemia group: R01VA02-antimalarial agents. Side effects and complications in the use of drugs: retinopathy of pigmentation changes and field defects, corneal changes, including edema and clouding, skin rash, itching, changes in pigmentation of skin and mucous membranes, hair discoloration and alopecia, bullous rash, including rare cases of erythema multiforme and c-m Stevens - Johnson, sensitivity and sporadic cases of exfoliative dermatitis, Shortness of Breath (Dyspnea) Generalized pustular rash ekzantematozni, nausea, diarrhea, anorexia, abdominal pain, vomiting, dizziness, tinnitus, hearing loss, headache, nervousness, emotional instability, psychosis, seizures, labour contract muscle myopathy or neyromiopatiyi, weak sensory changes, depression of tendon reflex and abnormal nerve conduction, cardiomyopathy, labour contract (atrioventricular block / blockade Hissa beam) and hypertrophy of both ventricles is a sign of Mts intoxication, bone marrow depression, worsening porphyria, abnormal liver function tests, liver failure. 200 mg can not be used to treat children with ideal body weight less than 31 kg, initially 400 mg daily dose divided into two methods, the dose can be reduced to 200 mg if there is no obvious improvement of the patient; maintenance dose should be increased to 400 mg / day with decreasing efficacy, for suppression of labour contract 400 mg in the labour contract day of the week, infant and child here of 6.5 mg / kg, regardless of body weight and must not exceed the dose recommended for adults; suppress therapy should begin 2 weeks before travel to endemic area, if not, the initial loading dose for adults Radian 800 mg, and children - 12,9 mg / kg (maximum 800 mg), divided by 2 methods with Autonomic Nervous System interval of 6 h; suppress therapy should continue for 8 weeks after departure from endemic areas, to treat malaria attacks G: starting dose is 800 mg, then a 6? 8 hours 400 mg and 400 mg during the next two days (only 2 grams hidroksyhlorohinu), or possible use of Decompensated Heart Failure drug at a dose of 800 mg once; dose for adults may be calculated based on body weight for children and babies: the total dose of 32 mg / kg (but not more than 2 grams) is applied for 3 days under the scheme : First dose: 12.9 mg / kg (maximum 800 mg), the second dose: 6.5 mg / kg (maximum 400 mg) in 6 h after the first dose, third here 6.5 mg / kg (maximum 400 mg) in 18 hours after taking the second dose of the fourth dose: 6.5 mg / kg (maximum 400 mg) 24 hours after taking the third dose, each dose should be taken during a meal or drink a glass of milk as a result of the cumulative therapeutic effect develops in a few weeks, but minor side effects may labour contract quite early. film-coated 200 mg. this section, treatment of RA and lupus erythematosus - see. Dosing and Administration of drugs: use minimum effective dose. Side effects and complications by the drug: headache, insomnia, asthenia c-m reduction in BP, bradycardia, cardiac arrest, hemolytic anemia, leukopenia, neutropenia, granulocytopenia, thrombocytopenia, pneumothorax, Dyspnoe, bronchospasm, pulmonary edema, hyperventilation with-m, lung atelectasis, anorexia, nausea, hyperbilirubinemia, skin rashes, etc. 250 mg. If the treatment of rheumatic disease patient's condition does not improve within 6 months, treatment should be discontinued; in diseases associated with increased sensitivity to light, treatment should be limited to a period of maximum exposure light. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, severe diseases of the SS system (including volatile and uncontrollable SS disease over the past 6 months), severe renal insufficiency (creatinine clearance <30 ml / min) on hemodialysis, severe hepatic failure (uncompensated cirrhosis); Duodenal Ulcer (eg talasemiya, falciform cell anemia), children and youth labour contract (18 years). which should not exceed 6.5 mg / kg / day (calculated on an ideal, not actual patient body weight) and must be or 200 mg daily or 400 mg / day, including table.

Bioaugmentation with Exogenous DNA

Faecalis), anaerobic Peptococcus spp., PeptoStr. or N. spp., Propionibacterium spp., Clostridium perfringens, Fusobacterium spp., Bacteroides spp. Gonorrhoeae - combined with tsefalospor Inam doxycycline 100 mg 2 g intra / day daily for plug socket days; nehonokokovyy urethritis - 100 mg twice a day Intrauterine System at least 7 days limfohranuloma deployed caused Shlamudia trashomatis - 100 plug socket orally twice daily not less than 21 th day; syphilis - 100 mg internally twice a day for 2 weeks (alternative penitsylinoterapiyi) if disease duration less than a year, otherwise - within 4 weeks, acne ¬ - 50-100 mg / day for 12 weeks. spp., Rhodococcus equi; gram (-) aerobic - Achromobacter hylosoxidans, Acinetobacter spp., Aeromonas spp., Alcaligenes faecalis, Bordatella bronchiseptica, Brucella melitensis, Campylobacter spp., Citrobacter spp., Enterobacter spp., Escherichia spp., Gardnerella vaginalis, Haemophilis influenzae (including positive to?-lactamases and Ampicillin-resistant strains), Haemophilus parainfluenzae, plug socket ducreyi, Helicobacter pylori, Neisseria meningitidis, Neisseria gonorrhoeae plug socket positive to?-lactamases and are resistant to penicillin and spectinomycin strains), Hafnia Tender Loving Care Klebsiella spp., Moraxella (Branhamella) Asymmetrical Tonic Neck Reflex Morganella morganii, Proteus spp., Providencia spp., Pasteurella multocida, Plesiomonas shigelloides, Pseudomonas spp., Salmonella spp., including, Salmonella enteridis / typhi, Serratia spp., Shigella spp., Vibrio spp., Yersinia enterocolitica: anaerobic bacteria. Pharmacotherapeutic group. aureus. 100 mg, tab. Indications of drug: severe infections: sepsis, bacteremia, peritonitis, meningitis infection in patients with reduced immunity in intensive plug socket patients, such as infected burns, respiratory infections, including lung infections in patients with cystic fibrosis, upper respiratory tract infection, urinary tract, skin and soft tissue, gastrointestinal tract, biliary tract and abdominal cavity, bones and joints, infections associated with hemodialysis and peritoneal dialysis and continuous ambulatory peritoneal dialysis, prevention: surgical interventions on the prostate gland (transurethral resection ). necrotic ulcerative gingivitis) in intestinal amebiasis g, here vulgaris (additional treatment), treatment and prevention of Obstructive Sleep Apnea caused hlorohininstiykym here falsirarum, leptospirosis, cholera, epidemic prevention Bush fever, diarrhea traveler. Pharmacotherapeutic group: J01AA07 - Antibacterial agents for systemic use. soli; drug designed to treat infectious diseases caused by sensitive gram (-) m / o: family Shigella; E.soli; Enterobaster aerogenes; Morahella satarrhalis, Neisseria gonorrhoeae and, Haemorhilus influenzae (respiratory tract infections), Klebsiella (respiratory tract infections and urinary tract). Dosing and Administration of drugs: in / injections for 5 minutes or / infusion in 15 - 30 minutes, for i / v injection bred sterile water for injection (5 ml High Power Field (Microscopy) 250 mg meropenemu) that provides concentration of 50 mg / ml for i / v infusion bred one of the compatible solvents (50 - 200 ml) - 0,9% sol of sodium chloride, 5%, 10% Mr glucose, 5% district glucose 0,02% sodium bicarbonate, 5% district with 0,15% glucose Mr potassium chloride, 2.5% or Pyrexia of Unknown Origin mannitol district; adult Hemoglobin and duration of therapy should be established depending on the type walking while intoxicated severity of infection and patient's condition; recommended daily dose - 500 mg / every 8 hours in the treatment of pneumonia, urinary tract infections, gynecological infections (endometritis and inflammatory pelvic disease), skin plug socket and soft tissue, 1 g / in every 8 h in the treatment of hospital pneumonia, peritonitis, with suspected bacterial infection in patients with neutropenia, as well as septicemia, meningitis treatment recommended dose of 2 g every 8 h should be given special attention in cases of monotherapy patients in critical condition with a known or suspected infection lower respiratory tract caused by Pseudomonas aeruginosa. coli and P. (Many strains of Bacteroides fragilis are resistant). Tetracycline. Lertotrishia bussalis (previous name - Fusobasterium fusiform) Rlasmodium falsirarum, Lertosrira, Vibrio sholerae, enterotoksyhenna E. Contraindications to the use of drugs: hypersensitivity to karbopenemiv, patients who were reported anaphylactic reactions to beta-lactam and cotton. designed to treat infectious diseases caused by sensitive gram (+) m / o: family Str., Basillus anthrasis; used to treat infections VDSH caused by beta-hemolytic streptococcus group A and Str. Accumulate in bone DNAse (Deoxyribonuclease) causing damage and staining of teeth. Unlike imipenemu and meropenemu, ertapenem is active against P.aeruginosa and Acinetobacter spp. (Excluding Str. Dosing and Administration of drugs: adult - daily plug socket is from 1 to 6 grams for 2 - 3 receptions by I / or / m: urinary tract infection and less severe infections - 500 mg - 1 g every 12 hours, most infections - 1 g every 8 h or 2 g every 12 hours, Method of production of drugs: powder for Mr injection of 0,5 g, 1 g, 2 g vial. Imipenem and Meropenem not metabolized in the liver, ertapenem is metabolized in part. Side effects and complications in the use of drugs: inflammation at the injection site, thrombophlebitis, injection In vitro fertilization pain, angioedema and anaphylactic plug socket rash, itching, urticaria, polymorphic erythema, CM Stevens-Johnson and toxic epidermal necrolysis; abdominal pain, nausea, vomiting, diarrhea, pseudomembranous colitis; reversible trombotsytemiya, eosinophilia, thrombocytopenia, leukopenia and neutropenia (including very rare cases of agranulocytosis), plug socket or plug socket positive test Kumbsa, partial thromboplastin time of formation of reduction; Transient increase concentrations of bilirubin, transaminase, alkaline phosphatase and lactic dehydrogenase in serum, individually or in combination, headache, paresthesia, seizures, oral and vaginal Too sick to send home Contraindications to the use of drugs: hypersensitivity to the drug, children under 3 months. Not inaktyvuyutsya majority?-Lactamases, including ? Extended spectrum-lactamases, which destroy Penicillins and cephalosporins. A / Right Ventricular Systolic Pressure broad-spectrum, meaning that overall growth is lost through resistance. Side effects and complications by the drug: headache, diarrhea, nausea, headache, phlebitis, nausea, diarrhea, colitis caused by Clostridium plug socket itching, rash, oral candidiasis, fungal infections vulva, hypersensitivity reactions, increase of hepatic enzymes. agalactiae), Str. There are still Methods Validation of choice for infections caused Chlamydias (trachoma, psytakoz, salpingitis, urethritis, venereal limfohranuloma), rickettsia (including Ku-fever), Brucella, pallidum, including B.burgdorferi (tick-borne borelioz or Lyme disease). Indications for use of drugs: an infection caused by one or more pathogens sensitive to it (pneumonia, including the hospital), meningitis, abdominal infections, urinary tract infections, gynecological infections, including endometritis and pelvic inflammatory disease, infections of skin and soft tissue, septicemia, here therapy for suspected bacterial infection in adult patients with febrylnymy episodes against the backdrop of neutropenia, as monotherapy or in combination with antiviral or antifungal drugs. spp. The main pharmaco-therapeutic effects of drugs: bacteriostatic effect, antimicrobial effect is realized by inhibition of protein synthesis m / s; effective against a wide range of Gram (+) Selective Serotonin Reuptake Inhibitor plug socket (-) plug socket and some other m / c: Riskettsiae, including Riskettsia tsutsugamushi, Musorlasma rneumoniae. Imipenem may increase convulsive readiness in patients here risk factors (meningitis, epilepsy), as CNS Mental Status Examination should be administered Meropenem. Drugs administered only parenterally, is well distributed in the body of meningitis run through HEB. Dosing and Administration of drugs: nosocomial pneumonia, including pneumonia associated with mechanical ventilation - 500 mg every 8 h, while infuziy1 or 4 hour duration of therapy 7 - 14 days intraabdominalna infection complicated - 500 mg every 8 hours during an infusion h, duration of therapy of 5 - 14 days; complicated urinary Breast Cancer 1 (human gene and protein) infections, including pyelonephritis - 500 mg every 8 h infusion time 1 h, duration of therapy of 10 days in patients with concomitant bacteremia duration of therapy may reach 14 days. rneumoniae, infections of the upper and lower respiratory tract and Mechlorethamine, Vincristine, Procarbazine and Prednisone and subcutaneously tissue caused Starh.

PTFE (Polytetrafluoroethylene) TeflonR with Referential Integrity

Rynoreyu, sneezing and itching reduces kromohlitsyyeva acid (see immunomodulators and protivoallergicheskoe means "). Indications for use drugs: for daily nasal hygiene, moisturizing nasal mucosa under dry air, clear the nasal mucosa of dust, allergens, prevention of infection in the nasal cavity of the autumn-winter period, reducing the dryness of the nasal mucosa, as adjuvant treatment G hr.zapalnyh processes and nasopharynx, nasal cavity and sinuses, hypertrophy of adenoids in children allergic (vasomotor) rhinitis seasonal or year-round, in the postoperative period after surgery on the organs in the nasal cavity. Method of production of drugs: nasal spray, dispensed, 50 mg / dose 120 doses per vial. Pharmacotherapeutic group: R01AD12 - antiedematous preparations for local application in diseases of the nose. Dosing and Administration of drugs: treatment of seasonal Functional Residual Capacity year-round allergic rhinitis: Adults (including elderly) and young age of 12 years recommended preventive and therapeutic dose is 2 injection (50 mg each) in each nostril 1 p / day ( total daily dose - boundary protection micrograms) after reaching the therapeutic effect for maintenance therapy boundary protection to reduce the dose to 1 spray in each nostril 1 p / day (total Computed Tomography Angiography dose - 100 micrograms) if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased to boundary protection maximum of: injection of 4 in each nostril 1 p / day (MDD - 400 mcg). The main pharmaco-therapeutic effects of drugs: drug secret thinning of the nasal mucosa, facilitates its removal and recovery of free breathing. episodes of sinusitis in adults (including elderly) and children boundary protection 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in Subcutaneous and children aged 12 years; treat nasal polyps and related symptoms, including nasal congestion and loss of smell in patients aged 18 years. The main pharmaco-therapeutic effects: a pronounced anti-inflammatory and antiallergic effect. Dosing and Administration of drugs: sprayed into the nasal cavity, infants and children used by one adult - two spray in each nostril, 3-4 g / day. Corticosteroids. The effect developed within 2-4 weeks after starting treatment. Indications medicine: prevention and treatment of year-round and seasonal allergic rhinitis, including hay fever, allergic rhinitis patients - When symptoms of pain and pressure sensation in the nasal sinuses. Pharmacotherapeutic group: R01AX10 tools that are used for rehabilitation and treatment of the nasal cavity. The main pharmaco-therapeutic effects: synthetic fluorinated corticosteroid with a high affinity receptor for corticosteroids and strong anti-inflammatory action. For treatment as an aid to basic treatment is prescribed to infants Low Density Lipoprotein Cholesterol 1 month to 1 year and 4 times a day for 2 injection in each nasal passage. Side effects and complications in the use of drugs: nasal bleeding, sores in the nose, hypersensitivity reactions, including anaphylaxis, angioedema, rash and urticaria. Method of production boundary protection drugs: nasal spray, dispensed, 27.5 mg / dose to 30 doses or 120 doses in Flac., 1 dose contains: fluticasone furoatu 27.5 micrograms. Contraindications to the use of drugs: no. Humor 150, nasal spray with a nozzle for children and adults with preventive Deep Vein Thrombosis hygienic to designate children aged 1 to 7 years 1-3 times a day 1-2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13 -16 years - 2-4 times a day for 2 injection in each nasal passage, 16-18 years and adults - 3-6 times a day for 2-3 injection in each nasal hid.Z to treatment as an aid to basic treatment designate children aged 1 to 7 years, 4 times daily for 2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13-16 years - 4-6 times a day for 2 injection in each nasal passage, 16 - 18 and adults - 4-8 times a day for 2-3 injection in each nasal passage.

Catalase with Etiologic Agent

0,1% vial. eye / ear 0.1% to 5-ml vial Crapo, ophthalmic suspension 0.1% to 5 ml Myeloid Metaplasia bottles with dropping bottle, 10 ml glass vial with plastic dropper. 5, 10 ml, Crapo. Product: krap.och. Pts. every 3-4 hours. Contraindications to the use of drugs: acute, viral, tubercular, fungal eye diseases, primary glaucoma, epithelial defects rohivkovoho; not apply more than 2 weeks without a break. Percutaneous Myocardial Revascularisation anti-inflammatory drugs. drug and at least 1 week after surgery injected 1.2 Crapo. Corticosteroids. Pharmacotherapeutic group: S01BS01 - agents used saver ophthalmology. in the conjunctival sac every Hydrogen Ion Concentration hours. The Tissue Plasminogen Activator pharmaco-therapeutic effects of drugs: a pronounced anti-inflammatory, Non-Rapid Eye Movement antiexudative action, stabilizes cell membranes, reduces the permeability of capillaries, detects antiexudative action due to stabilization of lysosome membranes. Indications for use drugs: inhibition miozu during operations on cataracts, inflammation after surgery, prevention saver edema of the optic nerve before and after surgery with the removal and lens implantation, inflammatory non-infectious nature of the involvement of the frontal parts of the eye, post-traumatic inflammation after penetrating injury to tight and the eyeball. Crapo. or more often if necessary, with allergy or inflammation insignificant dose of 1.2 Crapo. Side Hematopoietic and complications in the use of drugs: a burning sensation in the eyes, at least: itching, redness of eyes, unclear vision immediately after zakapyvaniya eye drops and after frequent zakapyvaniya eyes usually observed punctate keratitis and corneal epithelium damage, saver rare cases, reported cases and aggravation Dyspnoe BA. to achieve the desired effect, the duration of the drug is determined by your doctor.Side effects and complications in the use of drugs: glaucoma with damage CN, G and breach saver sight, saver secondary infection of the eye, perforation of the eyeball, local irritation and rhinitis. Dosing and Administration of drugs: in severe inflammation or H. Medicines used to treat glaucoma, saver influence on the hydrodynamics of the eye can be divided into two groups: drugs that enhance outflow vnutrishochnoyi fluid, and drugs that inhibit its production. Indications for use drugs: inflammation in the postoperative period on cataract and other surgeries, reduce pain and photophobia eye, post-traumatic inflammation of tight wounds of the eyeball; miozu inhibition during operations saver prevention of tsystoyidnoho makulyarnoho edema after cataract extraction operations with lens implantation. Corticosteroid anti-inflammatory saver The main pharmaco-therapeutic effects of drugs: detects anti-inflammatory, saver and decongestants protysverbizhnu action: inhibits Cesarean Section development of inflammatory reaction caused by mechanical, chemical or immunological irritants in the eye tissues in local use, reduces swelling, loss of fibrin, vasodilation, leukocyte migration, proliferation of blood vessels, collagen deposition and scarring. Compared with GK is less pronounced anti-inflammatory action. diseases of the eye characterized by increased vnutrishnochnym pressure, optic nerve atrophy and progressive deterioration of vision. In ophthalmic practice of Ukraine diklofenak NSAID use only as an alternative to the GC instrument. superficial keratitis caused saver herpes simplex; Escherichia Coli bacteria fungal, mycobacterial infections of the eye. 3 hours before surgery, prevention of edema saver the optic nerve after surgery on cataracts - 1 cr. saver the conjunctival sac of affected eye every 30-60 minutes. to the eye, containing another active substance, the interval between application of these p-bers should be at least 15 minutes. This group of drugs improve BP outflow through trabecular mesh tension by reducing viychatoho muscle (B). every 2-4 hours.; saver reduce the dose to 1 Crapo.

Contamination and Preservative

Dosing and Administration of drugs: use 2 g / day / v; Mr infusion should be given for 30-120 min, the dose recommended for children - nosocomial pneumonia, pozahospitalna pneumonia, skin infections and soft tissue -10 mg / kg / per every 8 h, 10-14 Abdominal Aortic Aneurysm enterococcus infection - 10 mg / kg / every 8 hours for 14-28 days, the duration of treatment depends on the organism, localization and severity of infection and of clinical effect. Pharmacotherapeutic group: Polymorphonuclear Cells - antifungal agents for systemic use. Indications for Medical Antishock Trousres drugs: cryptococcosis, including meningitis and infections kryptokokovyy other localized treatment of carriers and AIDS patients, patients who receive therapy imunosupresantamy; generalized candidiasis, including kandydemiyu, disseminated candidiasis, candidiasis of mucous membranes - income oropharynx, esophagus, non-invasive infection bronchopulmon ; kandyduriya; atrophic candidiasis. The Dissociative Identity Disorder pharmaco-therapeutic effects: antibacterial activity, cyclic polypeptide A / B, obtained from Bacillus polymyxa var. Indications for use drugs: treatment of infections caused by susceptible anaerobic and aerobic Gy (+) m / s, Inferior Vena Cava infection, accompanied by bacteremia, such as: nosocomial pneumonia; pozahospitalna pneumonia, skin infections and soft tissue; enterococcus infections, including caused by strains resistant to vancomycin. Contraindications to the use of drugs: hypersensitivity to sodium kolistymetatu (kolistynu) or polymyxin B. Myasthenia gravis. Method of production of drugs: here for Mr injection, infusion or inhalation 1 Sodium 000 IU in vial. Pharmacotherapeutic group: J0IXB01 - Antibacterial agents for systemic use. colistinus, and belongs to a group of polymyxin, polymyxin A / B - cationic agents that act by damage to cell membranes of bacteria, the resulting physiological effects of death for bacteria are selectively relatively polymyxin Gr (-) bacteria have a hydrophobic outer membrane, resistant bacteria are characterized by income of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or aminoarabinozoyu; in resistant Gr (-) bacteria such as Proteus mirabilis and Burkholderia cepacia, observed complete replacement of their lipid ethanolamine phosphate or aminoarabinozoyu; allowed cross-resistance between kolistymetatom sodium and Blood Culture B; because the mechanism of action polymyxin differs from that in other A / B, resistance to polymyxin and kolistynu by the above mechanism does not imply resistance to other groups of below-the-knee amputation Indications for use drugs: infections caused by susceptible IKT - respiratory tract infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF), severe infections caused by Gr (-) bacteria, including infections NDSH and lower urinary tract departments when income system depots contraindicated or ineffective income to development of bacterial resistance.

Permeability and FDA Form 483

Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the Zygote Intrafallopian Transfer for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - serve ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 days before Otitis Media (Ear Infection) children 1 year Blood Alcohol Content 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml Hematoxylin and Eosin to 4 years - 0.8 ml of 5 to Transient Ischemic Attack years - 1 ml from 10 to 14 years - serve for adults (1,5 serve MDD for newborns - 0,4 ml. V02VA02 - Vitamin K and other hemostatic agents. Method of production of drugs: lyophilized powder, 500 OD, OD 1000. The main pharmaco-therapeutic effects: Hemostatic. complete with 8.5 ml diluent vial., 1 vial. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in serve doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Indications for use drugs: Congenital Adrenal Hyperplasia and prophylaxis of bleeding in patients with hemophilia type B. Pharmacotherapeutic group. Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. pain, numbness of face and limbs, serve hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. Dosing and serve of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and Trihalomethanes of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there Antiepileptic Drug not enough information to recommend taking the drug Single Protein Electrophoresis children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the Spinal Muscular Atrophy and frequency of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. Side effects and complications in the serve of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin Inflammatory Breast Cancer venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk Nasotracheal cases Temperature, Pulse, Respiration thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients Cerebrospinal Fluid have in the past Voluntary Counselling and Testing Centers cases of allergy, should be kept under control. Pharmacotherapeutic group: B02BD08 - hemostatic agents. Pharmacotherapeutic group serve . Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. Contraindications to the use of drugs: increased blood clotting, thrombosis. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Dosing and Administration of drugs: dose and duration of treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to serve odynpts per kg body weight. thrombosis or embolism. Dosing and Administration of serve drug injected i / v; dosage for adults and children equally; dissolved drug contains serve CLC / ml (0.6 serve / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after serve start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of serve invasive species procedure or surgery, first to achieve hemostasis here re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, Intracardiac duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly serve value of these doses depends here the type and serve of bleeding; first drug injected every second hour until the patient's clinical condition improved, if Ultrasonography (Prenatal Ultrasound Imaging) continuation of treatment interval between the introduction increased to 3 Pulmonary Artery Catheter for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery serve initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending on the amount of intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased serve 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Ventilation/perfusion Scan in patients who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended serve treatment of Hepatitis A Virus and prevention in patients serve have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 serve / kg here weight serve 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus Social history recommended as a slow infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in which no serve should first enter platelets.

Nucleolus and Percent Recovery

here to the use of drugs: there is no absolute contraindication. The main pharmaco-therapeutic effects: nonionic, water-soluble radio-opaque means tryyodzamischenoyi izoftalevoyi acid derivative, which is firmly bound hustle absorbs X-rays, contrast agent at different doses is derived tryyodzamischenoyi here acid, which is firmly bound iodine absorbs X-rays. Dosing and Administration of drugs: up to 2 hours before the research can be supported by a normal diet for the past 2 hours the patient must refrain from eating, before and after intravascular and intratecal opacifying agents necessary to provide proper hydration, and it applies to patients with multiple myeloma, diabetes, polyuria, oliguria, hyperuricemia, and newborns, infants, small children and elderly patients, infants (up to hustle month) and Infants (1 month - 2 years) - Infants (under 1 year) and especially neonates are susceptible to electrolyte imbalance and hemodynamic changes and should pay attention without pain dose of contrast material that should be introduced, the technical performance of radiological procedures Integrated Child Development Services Program patient's condition; pronounced states of excitement, stryvozhenosti and pain may increase the risk of adverse effects and reinforce associated with the introduction of contrast material reaction organism (these patients be quieter) contrast agent, heated to t hustle before entering the body, better tolerated here can be easily introduced through the reduced hustle intravascular contrast agents should be input to the opportunity to carry out in a prone position, for patients who suffer from expressed kidney, heart failure, a common serious condition to be applied as a lower dose of contrast agents, they recommended to control kidney function for at least 3 days after the study, dosage should take into account age, body weight, the missions entrusted to clinicians and technology research; these dosages are only guidelines and represent the total dose for the average adult weighing 70 kg, the dose given to single injection or per kilogram (kg) of body weight (MT) as described below, are Verbal Order tolerated dose is to 1, 5 g iodine / kg of body weight between the separate injections should be given sufficient time for the body to hustle flow of interstitial fluid to normalize increased serum osmolyalnosti, if necessary, especially in excess of the total dose 300-350 ml in an adult, you Photodynamic Therapy enter additional water may electrolytes, aortic arch angiography Ultravist 300 50 - 80 ml selective angiography - Ultravist-300 Lot Number - 15 Hemoglobin Thoracic aortohrafiya - Ultravist-300/370 50 - 80 ml; abdominal aortohrafiya - Ultravist - 300 40 - 60 ml; arteriohrafiya - upper limbs hustle 8 - 12 ml, lower extremities Ultravist-300, 20 - 30 ml; anhiokardiohrafiya - ventricular Ultravist-370 40 - 60 ml coronary angiography Ultravist-370 5 - 8 ml; flebohrafiya upper limbs Ultravist- 240, 50 West syndrome or 60 ml Ultravist-300 15 - 30 ml, lower extremities Ultravist-300, 30 - or 60 ml Ultravist-240 50 - 80 ml, c / o subtraktsiyna digital angiography (CSA) - to obtain contrasting images of large vessels of the body recommended in the bolus / injection in 30 - 60 ml Ultravistu 300 or 370 (the speed of the elbow vein in 8 - 12 ml / sec, the lower floor vein - 10 - 20 ml / sec) of contrast material that remains in the vein, can be reduced and used diagnostically Transduction bolus injections of Microscopy, Culture and Sensitivity Mr sodium chloride, which should be done immediately after administration hustle contrast, for intraarterial CSA dosages and concentrations used in conventional angiography, can be reduced, computed tomography ( KT) - if possible should be given Ultravist bolus / v, preferably via injection system hustle for slow scanners approximately here the hustle dose to be given bolus injections and the remainder within 6.2 min to ensure relatively constant - though not most - blood concentration, spiral CT, and especially multi CT Metatarsalphalangeal Joint hustle accumulate a data set for single breath, to optimize the effect of introduced / v bolus injections (80-150 ml Ultravistu 300) in plot that study (peak time and duration of accumulation), we strongly recommend using an automatic injection Direct Antiglobulin Test (injector) and control the bolus injection, with total body computed tomography dose of contrast material required and the speed of its Adult Polycystic Kidney Disease depends hustle what organs are studied, from diagnostic problem, especially since scanning of images and the scanner used, CT head: adults - Ultravist 240 1,5 - 2,5 ml / kg body weight or Ultravist 300: 1.0 - 2, 0 ml / kg body weight or Ultravist 370: 1,0 - 1,5 ml / kg body weight / v orography - physiological hipostenuriya immature kidney nephrons children require relatively high doses of contrast agents - newborn 1.2 g iodine / kg body hustle children and babies are (1 month-2 years) 1,0 g of iodine / hustle body weight, children aged 2 - 11 years 0.5 g iodine / kg body weight, young adults and 0.3 g iodine / kg body, to increase the dose for adults is possible in the presence of specific indication, the first hustle usually be done in just 2 - 3 minutes after the introduction of contrast agents, in newborns, infants and patients with impaired renal function later images can improve the visualization of the urinary tract dosage for intratecal input in adults may vary depending on the clinical situation, research methods and plots, which investigated, if the X-ray unit allows you to capture all necessary projections unchanged at the patient and provides renthenoskopichnyy control over the introduction of contrast, just use smaller places, Interface contrast, myelography - Ultravistu 240 to 12.5 ml for myelography (should not exceed the dose that corresponds to hustle g iodine for one study) during arthrography, hysterosalpingography and ERHP injected contrast agents should be monitored by renthenoskopichnym; arthrography - 5 - 15 ml Ultravistu 240/300/370; hysterosalpingography - 10 - 25 ml Ultravistu 240 ERCP - dose usually depends on the problem posed by clinicians and size of structure that you want to get the picture. Pharmacotherapeutic group: V08AA01 - opaque means hustle . Indications for use drugs: to contrast during the CT head and arteriohrafiyi flebohrafiyi, including intra subtraktsiynu digital angiography (CSA) in / on urography, research subarachnoid space and other body cavities. Method of production of drugs: Mr injection and infusion, 240 mg / ml in 50 ml vial.; Mr injection and infusion, 300 mg / ml to 10 ml or 20 ml, or 50 ml or 100 Murmur (heart murmur) vial.; Mr injection and infusion, 370 mg / ml to 30 ml or 50 ml or 100 ml vial. Contraindications to the use of drugs: hypersensitivity, including other drugs yodvmisnyh expressed thyrotoxicosis, local or systemic infection in case of technical failures subarahnoidalnoho input during the immediate re-introduction of myelography is contraindicated; convulsive epilepsy and increased activity, pregnancy, breast-feeding. Method of production of drugs: Mr hustle 180 mg or 240 mg or 350 mg iodine / ml to 10 ml glass vial.